Repligen Corporation $RGEN Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio decreased its holdings in Repligen Corporation (NASDAQ:RGEN) by 4.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 16,530 shares of the biotechnology company’s stock after selling 787 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Repligen were worth $2,056,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of RGEN. Price T Rowe Associates Inc. MD grew its stake in shares of Repligen by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock worth $962,711,000 after purchasing an additional 430,039 shares in the last quarter. Nuveen LLC bought a new position in shares of Repligen in the first quarter worth $35,536,000. Artemis Investment Management LLP grew its stake in shares of Repligen by 110.1% in the first quarter. Artemis Investment Management LLP now owns 323,229 shares of the biotechnology company’s stock worth $41,128,000 after purchasing an additional 169,397 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of Repligen by 17,721.1% in the first quarter. GAMMA Investing LLC now owns 121,896 shares of the biotechnology company’s stock worth $15,510,000 after purchasing an additional 121,212 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its stake in shares of Repligen by 64.0% in the first quarter. T. Rowe Price Investment Management Inc. now owns 260,848 shares of the biotechnology company’s stock worth $33,191,000 after purchasing an additional 101,791 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $145.23 on Friday. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26. The stock has a market capitalization of $8.17 billion, a price-to-earnings ratio of -580.90, a PEG ratio of 2.69 and a beta of 1.08. The stock’s fifty day simple moving average is $121.84 and its 200 day simple moving average is $125.49. Repligen Corporation has a 52-week low of $102.96 and a 52-week high of $182.52.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.03). The company had revenue of $182.37 million during the quarter, compared to analyst estimates of $174.62 million. Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The business’s revenue was up 14.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts forecast that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $180.00 price target on shares of Repligen in a research note on Wednesday, September 3rd. Wall Street Zen cut Repligen from a “buy” rating to a “hold” rating in a research report on Sunday, June 29th. Royal Bank Of Canada reiterated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Tuesday, September 2nd. Wells Fargo & Company lowered their price target on Repligen from $180.00 to $175.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 30th. Finally, Stephens upgraded Repligen to an “overweight” rating and set a $160.00 price target on the stock in a research report on Tuesday, July 22nd. Ten equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $168.08.

Insider Activity

In related news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the acquisition, the director directly owned 1,800 shares of the company’s stock, valued at $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. 1.20% of the stock is owned by insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.